EU POLICY AGAINST FALSIFIED MEDICINES: OPTIONS FOR FURTHER DEVELOPMENT

Authors

  • Krasimira Valcheva University of National and World Economy, Management and Administration Faculty, Sofia

DOI:

https://doi.org/10.12955/peb.v1.32

Keywords:

falsified medicine, policy, regulations, supply chain, track-and-trace

Abstract

The globalization of trade and internet access significantly increased the health risks associated with falsified medicines. International organizations, pharmaceutical companies and national governments developed a wide variety of measures to combat their pervasive penetration into the legal supply chains. However, the lack of harmonization, broad acceptance and legally bound enforcement obstructed their endeavours. The unsatisfying outcomes resulted in enhanced supranational cooperation focused on strengthening the pharmaceutical regulatory frameworks and the improvement of patient protection. 

In 2011 the European Union joined the global fight with the adoption of Directive 2011/62/EU that became known as the Falsified Medicine Directive. It is legally binding for Member States and amends the fundamental for the pharmaceutical sector Directive 2001/83/EC. The objective of the present paper is to verify if it represents a comprehensive tool for effective prevention of the access of falsified medicines in the European legal pharmaceutical supply chains. The results revealed that although it is rather detailed, there are areas that could be further developed and improved when compared to analogical policies and initiatives.

References

Albin, P. (2017). When Serialization ≠ Anti-Counterfeiting. Retrieved from https://www.linkedin.com/pulse/when-serialization-anti-counterfeiting-albin-paul/

Boxtel, C. J. van, Santoso, B., & Edwards, I. R. (2008). Drug benefits and risks: international textbook of clinical pharmacology. Amsterdam: Ios Press.

Commission Delegated Regulation (EU) 2016/161 of 2 October 2015, Brussels, Belgium, 2016. Retrieved from https://eur-lex.europa.eu/eli/reg_del/2016/161/oj

Committee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products; Board on Global Health; Institute of Medicine; Buckley GJ, Gostin LO, editors (2013). Countering the problem of falsified and substandard drugs. Washington (DC): National Academies Press. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK202530/ doi: 10.17226/18272

Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011, Strasbourg, France, 2011. Retrieved from https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32011L0062

Drug Quality and Security Act: Title II Drug Supply Chain Security, 113th Congress, Public Law No: 113-54 (11/27/2013)

EDQM & Council of Europe (2016). Council of Europe model for a network among single points of contact to combat counterfeiting/falsifying medical products and similar crimes. Retrieved from https://www.edqm.eu/sites/default/files/spocs_network_model_en_april_2016.pdf [Accessed 26 April 2019]

EMA (2019). European medicines regulatory network - Medicines Agency. Retrieved from https://www.ema.europa.eu/en/about-us/how-we-work/european-medicines-regulatory-network#-benefits-of-the-network-for-eu-citizens-section

European Commission (2011). Memo 11/91: Q&A: Directive on falsified medicines. Retrieved fromhttps://ec.europa.eu/commission/presscorner/detail/en/MEMO_11_91

Federal law on circulation of medicines № 61-FZ. Retrieved from https://www.unodc.org/res/cld/document/rus/federal-law-on-circulation-of-medicines_html/Russian_Federation_Federal_Law_On_Circulation_of_Medicines_61-FZ_EN.pdf

IFPMA (n.d). Falsified medicines- Collective fight. Retrieved from https://www.ifpma.org/topics/falsified-medicines/

IRACM (n.d). Commitment and strategy: Prevention. Retrieved from http://www.iracm.com/en/commitment-and-strategy/prevention/

Mackey, T. K., & Nayyar, G. (2017). A review of existing and emerging digital technologies to combat the global trade in fake medicines. Expert Opinion on Drug Safety, 16(5), 587–602. doi: 10.1080/14740338.2017.1313227

Modor Intelligence (2018). Europe Over-the-Counter (OTC) Drugs Market - Segmented by Product, and Geography - Growth, Trends and Forecasts (2018 - 2023). Retrieved from https://www.researchandmarkets.com/reports/4472702/europe-over-the-counter-otc-drugs-market

Newton, P. N., Amin, A. A., Bird, C., Passmore, P., Dukes, G., Tomson, G., … White, N. J. (2011). The Primacy of Public Health Considerations in Defining Poor Quality Medicines. PLoS Medicine, 8(12). doi: 10.1371/journal.pmed.1001139

Noone, J., & Blanchette, C. M. (2017). The value of self-medication: summary of existing evidence. Journal of Medical Economics, 21(2), 201–211. doi: 10.1080/13696998.2017.1390473

OZKAYA, E. (2017). DIGITAL FACTORY TRANSFORMATION BEYOND SERIALIZATION COMPLIANCE. RETRIEVED FROM HTTPS://PHARMACEUTICALCOMMERCE.COM/MANUFACTURING-AND-PACKAGING/DIGITAL-FACTORY-TRANSFORMATION-BEYOND-SERIALIZATION-COMPLIANCE/

World Health Organization (1999). Counterfeit drugs: guidelines for the development of measures to combat counterfeit drugs. Geneva, Switzerland.

World Health Organization (2016). Report: Substandard/spurious/falsely-labelled/ falsified/counterfeit medical products. Retrieved from http://apps.who.int/gb/ebwha/pdf_files/WHA69/A69_41-en.pdf

World health Organization (2017). WHO Global Surveillance and Monitoring System for substandard and falsified medical products. Retrieved from https://apps.who.int/iris/bitstream/handle/10665/326708/9789241513425-eng.pdf?ua=1

Downloads

Published

2020-11-16

How to Cite

Valcheva, K. . (2020). EU POLICY AGAINST FALSIFIED MEDICINES: OPTIONS FOR FURTHER DEVELOPMENT. Proceedings of CBU in Economics and Business, 1, 147-153. https://doi.org/10.12955/peb.v1.32